Conference

29 sep 2016 Christof Swaak speaks at IBC’s "Competition Law Challenges in the Retail Sector 2016" conference in Brussels

29 sep 2016 Christof Swaak speaks at IBC’s "Competition Law Challenges in the Retail Sector 2016" conference in Brussels

29 sep 2016 Christof Swaak speaks at IBC’s "Competition Law Challenges in the Retail Sector 2016" conference in Brussels

23.08.2016

On 29 September 2016, Christof Swaak will speak at the “Competition Law Challenges in the Retail Sector 2016” conference organised by IBC.

Christof will review recent Cartel and Private Litigation cases and will provide an update on the Damages Directive.

Related news

06.05.2021 EU law
Abuse of economic dependence: lessons drawn from the first judgments

Short Reads - On 22 August 2020, the ban on abuse of economic dependence was implemented in Belgium (Article IV.2/1 of the Code of Economic Law). Now that almost a year has passed and the first judgments have been rendered, we assess what first lessons can be drawn from these judgments. The rulings show that the ban is regularly relied upon in court and has lowered the hurdle for plaintiffs to make their case.

Read more

01.04.2021 NL law
Slovak Telekom: ECJ on essentials of the ‘essential facilities’ doctrine

Short Reads - Only dominant companies with a “genuinely tight grip” on the market can be forced to grant rivals access to their infrastructure. According to the ECJ’s rulings in Slovak Telekom and Deutsche Telekom, it is only in this scenario that the question of indispensability of the access for rivals comes into play. In the assessment of practices other than access refusal, indispensability may be indicative of a potential abuse of a dominant position, but is not a required condition.

Read more

01.04.2021 NL law
Pay-for-delay saga ends with nothing new; but pharma quest continues

Short Reads - On 25 March 2021, the ECJ ended the Lundbeck pay-for-delay saga by dismissing the appeals from Lundbeck and five generic manufacturers against a European Commission ‘pay-for-delay’ decision. Following its recent Paroxetine judgment, the ECJ found that Lundbeck’s process patents did not preclude generic companies being viewed as potential competitors, particularly since the patents did not represent an insurmountable barrier to entry. In addition, the patent settlement agreements constituted infringements "by object".

Read more